Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

Company: Navamedic Date: 2025-07-15 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

# Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

Oslo, 15 July 2025: Reference is made to the stock exchange announcement  

published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on  

23 June 2025, regarding Navamedic entering into an asset purchase agreement for  

the acquisition of the business of dne pharma AS for a total consideration of up  

to NOK 225 million, whereby NOK 185 million is payable at closing, and the  

remaining NOK 40 million is payable in two tranches subject to achievement of  

certain agreed sales volumes for the acquired products (the "Transaction").  

  

Navamedic is pleased to announce that the Transaction has today been  

successfully completed.  

  

The Acquisition encompasses dne pharma's business, including product portfolio,  

key employees and all essential contracts of the business, intellectual  

property, licenses, and distribution agreements. The product portfolio includes  

prominent products such as Ventizolve® (intranasal naloxone spray for opioid  

overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for  

opioid substitution therapy. The acquired business will be integrated into  

Navamedic's existing commercial platform, enabling rapid market access and  

geographic expansion across the Nordics and selected European markets.  

  

"This acquisition represents a significant step in our strategic expansion into  

the rapidly growing field of addiction treatment and is well aligned with our  

long-term growth ambitions. Thanks to the strong collaboration among all parties  

involved, the transaction was completed in a smooth and efficient manner. We are  

pleased that the General Meeting unanimously approved the Rights Issue  

yesterday, and we are sincerely grateful for the continued support of Kistefos  

and the other underwriters," said Kathrine Gamborg Andreassen, CEO of Navamedic.  

  

The Acquisition is financed through a combination of new debt in the amount of  

NOK 110 million from Nordea Bank Abp, filial i Norge ("Nordea") and a rights  

issue approved at an extraordinary general meeting of Navamedic on 14 July (the  

"Rights Issue"). Navamedic has been assisted by DNB Carnegie a part of DNB Bank  

ASA ("DNB Carnegie") and Advokatfirmaet Thommessen ("Thommessen") in connection  

with the Acquisition, and Navamedic has been granted a bridge loan from Nordea  

enabling completion of the Acquisition before completion of the Rights Issue.  

Navamedic has retained DNB Carnegie, and Nordea Corporate Finance, a part of  

Nordea Bank Abp, filial i Norge as managers and Thommessen as legal advisors for  

the Rights Issue.  

  

"We are very pleased closing this transaction with Navamedic and we are  

confident that the Navamedic team will continue to grow the opioid substitution  

business developed by dne pharma, in particular the Ventizolve® products" says  

Geir Ove Engeset, CEO of dne pharma as.  

  

For further information, please contact:  

  

Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: Lars.Hjarrand@navamedic.com,  

or  

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail:  

kathrine@navamedic.com.  

  

About Navamedic  

  

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's  

quality of life by being a reliable supplier of high-quality prescription,  

consumer health, and hospital products to hospitals and pharmacies. Our growing  

product portfolio has been carefully selected to meet current public health  

concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to  

empower people to live healthier and more fulfilling lives.  

  

What sets us apart is our deep-rooted commitment to understanding the needs and  

requirements of the countries where we are present. Our local insight and  

competence enable us to understand the specific needs of each country where we  

operate and ultimately to gain market access. This makes us a preferred partner  

for international companies expanding their footprint across the Nordics and  

Benelux regions, through either in-licensing or out-licensing. Navamedic has  

been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is  

headquartered in Oslo, Norway. For more information, please visit  

www.Navamedic.com  

  

Aboutdne pharma/Pharma Production  

  

Prior to closing of the Transaction, dne pharmawas a Norwegian developer and  

distributor of addiction and pain therapies, including opioid substitution  

treatments and emergency overdose medications. dne pharma's wholly owned  

subsidiary, Pharma Production AS, will continue to manufacture and supply the  

product portfolio recently acquired by Navamedic, as well as concentrate on  

contract manufacturing and development services, including analytical services,  

supporting the long-term need for national pharmaceutical production capacity.  

https://pharmaproduction.no (https://eur02.safelinks.protection.outlook.com/?url=  

https%3A%2F%2Fpharmaproduction.no%2F&data=05%7C02%7Cole.henrik.eriksen%40navamedi  

c.com%7C4a5078d22d7d47a7384e08ddc37340f3%7Ca5635f8e246b48e094e8806923fb2a69%7C0%7  

C0%7C638881621997591634%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwL  

jAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qy  

wslRKXkTVBe7yNmRJjZ2hkA9pxdsfG2qFLSu41gA8%3D&reserved=0).  

  

This information is subject to the disclosure requirements pursuant to Section 5  

\-12 the Norwegian Securities Trading Act.